Achieve Life Sciences (ACHV) Equity Average (2016 - 2026)
Achieve Life Sciences (ACHV) has disclosed Equity Average for 16 consecutive years, with $16.1 million as the latest value for Q1 2026.
- Quarterly Equity Average rose 3.27% to $16.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $16.1 million through Mar 2026, up 3.27% year-over-year, with the annual reading at $21.2 million for FY2025, 118.07% up from the prior year.
- Equity Average for Q1 2026 was $16.1 million at Achieve Life Sciences, down from $27.6 million in the prior quarter.
- The five-year high for Equity Average was $45.9 million in Q2 2024, with the low at $1.3 million in Q4 2023.
- Average Equity Average over 5 years is $19.2 million, with a median of $17.3 million recorded in 2022.
- The sharpest move saw Equity Average crashed 85.1% in 2022, then soared 1918.42% in 2024.
- Achieve Life Sciences' Equity Average stood at $4.7 million in 2022, then plummeted by 72.29% to $1.3 million in 2023, then soared by 1918.42% to $26.1 million in 2024, then increased by 5.46% to $27.6 million in 2025, then crashed by 41.6% to $16.1 million in 2026.
- Per Business Quant, the three most recent readings for ACHV's Equity Average are $16.1 million (Q1 2026), $27.6 million (Q4 2025), and $37.6 million (Q3 2025).